---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-105928"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:25:51.100961+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acurx discontinues Phase 2b ibezapolstat trial early on high cure rates, no safety concerns; Phase 3 accelerated

## Summary
- Phase 2b discontinued after blinded data showed high clinical cure rates for ibezapolstat and vancomycin, with no emerging safety concerns.
- Company expects to advance ibezapolstat to Phase 3 more expeditiously; topline efficacy results to be reported promptly.
- Ibezapolstat is first-in-class, FDA QIDP/Fast-Track-designated antibiotic for C. difficile infection, potentially first new antibiotic class in 30+ years.
- Decision also influenced by site maintenance costs and slow enrollment due to COVID-19; Independent Data Monitoring Committee will not perform interim analysis.

## SEC filing metadata
- accession: 0001104659-23-105928
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465923105928/0001104659-23-105928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465923105928/tm2327257d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-105928
- JSON: https://secwatch.observer/filing/0001104659-23-105928.json
- Plain text: https://secwatch.observer/filing/0001104659-23-105928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.